Clinical trial · Observational
Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon
NCT01333735CI-TRIAL-00019048COG AGEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to investigate the impact of adjuvant chemotherapy on cognitive function in patients aged over 65 and suffering from breast cancer or colon.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Patients with chemotherapy group
- description
- Patients with breast or colon cancer must beginning a chemotherapy (colon group was ended)
- label
- Patients without chemotherapy group
- description
- patient with breast or colon cancer should not receive chemotherapy (colon group was ended)
Primary outcomes (1)
- measure
- impact of memory impairment
- timeFrame
- Before chemotherapy (baseline), end of chemotherapy and follow-up up to 24 months after chemotherapy
- description
- Assessing the impact of memory impairment induced by chemotherapy and study their evolution over time, with patients over 65 years treated in the adjuvant setting for breast cancer. Evaluated by auto-questionnary an tests with a neuropsychologist
Secondary outcomes (5)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 66 Years
Show eligibility criteria text
Inclusion Criteria for patients with chemotherapy : * Patient(e) aged over 65 years * Non metastatic breast cancer * Adjuvant chemotherapy Breast cancer: FEC, including Docetaxel Protocols * No major cognitive impairment * Lack of personality disorders and psychiatric disorders evolutionary * Having signed the informed consent of study participation Inclusion Criteria for patients without chemotherapy (control group): * Patient(e) aged over 65 years * Breast cancer * Patients receiving no adjuvant chemotherapy * No major cognitive impairment * Lack of personality disorders and psychiatric disorders evolutionary * Having signed the informed consent of study participation * Matching on age, sex, cultural level and tumor location Exclusion Criteria for patients with chemotherapy : * Metastatic * Cancer primitive other than breast * Patients under 65 years * Patients with adjuvant chemotherapy is associated with targeted therapy * Patients who have received other cancer treatments (chemotherapy or radiotherapy brain) * disorders of higher functions existing in the administration of chemotherapy * Pathology psychiatric evolutionary * Refusal of participation * Patients unable to meet the cognitive tests * Drug use * Heavy drinking
References
Publications (0)
Data not yet available
No reference posted for this study.